ARPO
Aerpio Pharmaceuticals Inc
Aerpio Pharmaceuticals Inc historical holders
total: 1
Scion Asset Management Aerpio Pharmaceuticals Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2021 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2021 Q2
Michael Burry has been an institutional investor in Aerpio Pharmaceuticals Inc (ARPO) since 2021 Q1. According to 2025 Q3 report, Michael Burry doesn't hold any shares. The fund/company first acquired ARPO in 2021 Q1, initially purchasing 1,000,000 shares. Since the initial investment, Scion Asset Management has made 1 more transaction in this position.
When did Michael Burry exit their ARPO position?
Michael Burry no longer holds Aerpio Pharmaceuticals Inc (ARPO). They sold off their entire position in 2021 Q2, closing out an investment that began in 2021 Q1.
When did Michael Burry first invest in ARPO?
Michael Burry first invested in Aerpio Pharmaceuticals Inc (ARPO) in 2021 Q1 at the reported quarter-end price of $1.29 per share, acquiring 1,000,000 shares in their initial purchase.
What is Michael Burry's average cost basis for ARPO?
Based on historical transaction data, Michael Burry's estimated cost basis for Aerpio Pharmaceuticals Inc (ARPO) is approximately $1.29 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $1.29
- Weighted AVG sell price:
- $1.29
ARPO transactions history by Scion Asset Management
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q2
|
0.00%
|
0
|
$1.29
|
|
-100% (-1,000,000)
|
-1.11%
|
|
2021 Q1
|
1.11%
|
1,000,000
|
$1.29
|
$1,290,000
|
new
|
+1.11%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.